In a report released today, Laura Sutcliffe from UBS maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a ...

The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.

Telix Pharmaceuticals Limited today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx ...

ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical ...

Key Takeaways Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for ...

Is now the time to look at the biotech flyer? The post Telix shares slip 11% from highs. Time to buy this high flying biotech ...

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S ...

Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...

As we expected, no-moat Telix’s slightly updated product, Gozellix, has received US regulatory approval. Like Illuccix, which contributes practically all of Telix’s current revenue ...